ADDICTIONS AND MENTAL HEALTH
The Michael G. DeGroote Centre for Medicinal Cannabis Research is investigating the nature of cannabis use for various mental health indications, such as anxiety and bipolar disorder. The Centre is also examining unintended consequences, like the emergence of cannabis use disorder in younger demographics, of its use.
The Centre’s research strives to advance existing clinical work investigating the particular constituents of cannabis, especially cannabidiol, as a therapeutic agent, while managing the risks associated with high tetrahydrocannabinol dosing.
To read our statement on industry partnerships please read the Industry Partnership Statement 2018 (PDF).
Projects
Trajectories of Cannabis Misuse in Emerging Adults Learn More About the Trajectories Project
This project leverages an existing longitudinal observational cohort to characterize patterns of change in cannabis use over time among individuals in their early twenties, including post-legalization.
James MacKillop, PhD
Using Crowdsourcing to Understand Cannabis Use and Misuse in Legally Regulated Environments Learn More About the Crowdsourcing Project
This project is collecting data on cannabis use and misuse in U.S. states where cannabis is already legal to inform the legalization of cannabis in Canada.
Michael Amlung, PhD
Understanding Reward, Value and Motivation in Cannabis Use Disorder Learn More About the Motivation Project
This project is using functional magnetic resonance imaging (fMRI) to understand the dysregulation of the brain’s motivational neurocircuitry in cannabis use disorder.
Iris Balodis, PhD
Approaches to Treat Cannabis Misuse in University Students: A Systematic Review
This project is synthesizing the existing literature on interventions to reduce the harm from cannabis in post-secondary environments.
Catharine Munn, MD, FRCPC
Efficacy and Mechanisms of Cannabinoids as Novel Anxiolytics: A Pilot Study
This project is investigating novel formulations of cannabinoid products as promising medications for treating anxiety disorders.
Michael Van Ameringen, MD, FRCPC